trial · primary record
varsetatug masetecan
Colo-rectal Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 368 |
| Primary completion | 2029-02 |
| Primary endpoint | Part 1 - Safety and tolerability of varsetatug masetecan in combination with bevacizumab + 5-FU + leucovorin |
| Registry ID | NCT07900165 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:56.758Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07900165
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.